PS
Peter Schmid
Barts Cancer Institute, University of Sussex, Charité – Universitätsmedizin Berlin, Technical University of Munich, Imperial College London, Ludwig-Maximilians-Universität München
Research areas: Medicine · Oncology · Breast Cancer Treatment Studies · Advanced Breast Cancer Therapies · Cardiovascular and exercise physiology
0000-0001-9817-5228
About
Professor Schmid is the clinical director of the Breast Cancer Centre and an honorary consultant medical oncologist at St. Bartholomew’s Hospital. He was appointed in 2013 as Chair in Cancer Medicine at Barts Cancer Institute (BCI), Queen Mary University London. Professor Schmid is the Lead of the Centre of Experimental Cancer Medicine at BCI, overseeing the conduct of early phase trials at St. Bartholomew’s Hospital and BCI. He leads the academic breast cancer programme at St. Bartholomew’s Hospital and BCI.
Employment
-
Barts Cancer Institute Professor of Cancer Medicine and Honorary Consultant in Medical Oncology, Centre Lead, Centre for Experimental Cancer Medicine2013 - Present
-
University of Sussex Foundation Chair of Cancer Medicine2010 - 2013
-
Imperial College London Senior Clinical Lecturer & Honorary Consultant in Medical Oncology, Director Hammersmith Early Clinical Trials Unit2005 - 2010
Education
- 1999 - 2005
- 1993 - 1998
- 1992 - 1997
- 1990 - 1992
Projects & Funding
-
DIAMOND - An open-label randomised, phase II trial of Datopotamab deruxtecan plus Durvalumab versus Datopotamab deruxtecan in patients with PDL1-negative metastatic triple-negative breast cancer AstraZeneca (United Kingdom)2025 - 2029
-
Barts ECMC Cancer Research UK2023 - 2028
-
BARBICAN: A randomized, open-label Phase II study to determine the contribution of ipatasertib to neoadjuvant chemotherapy plus atezolizumab in women with triple-negative breast cancer Roche (Switzerland)2018 - 2027
-
ECLIPSE - A phase II study investigating preoperative combination strategies for immunotherapy in patients with untreated, operable ER+, HER2-negative primary breast cancer Roche (Switzerland)2017 - 2024
-
Comprehensive Analysis of Circulating Biomarkers in breast cancer patients Barts Charity2015 - 2018
-
CRUKE/13/014: CEDAR – A Phase II, randomized, open-label study of the antisense oligonucleotide OGX-427 in combination with first-line chemotherapy in advanced squamous cell lung cancers Cancer Research UK2014 - 2018
-
TORCMEK - A Phase Ib/IIa study of AZD2014 in combination with Selumetinib in patients with advanced Triple-Negative Breast Cancer and Non-Small-Cell Lung Cancers Cancer Research UK2014 - 2018
-
CRUKE/12/051: PAKT - A Phase II, randomized, placebo-controlled study of paclitaxel in combination with the AKT inhibitor AZD5363 in triple-negative advanced or metastatic breast cancer Cancer Research UK2014 - 2018
-
Phase II window of opportunity study of short-term preoperative treatment with enzalutamide in patients with triple negative breast cancer Astellas Pharma Europe2014 - 2018
-
A randomized Phase II window of opportunity study of short-term preoperative treatment with enzalutamide plus exemestane versus exemestane alone in patients with triple negative breast cancer Astellas Pharma Europe2014 - 2018
-
MANTA - A randomized Phase II study of Fulvestrant in combination with AZD2014 or Everolimus or Fulvestrant alone in ER-positive advanced or metastatic breast cancer AstraZeneca2013 - 2018
-
Functional characterisation of the novel transcription factor Vav-interacting kinase 1 (Vik-1) in breast cancer Breast Cancer Campaign2012 - 2015
-
Identification and characterisation of novel, small molecule inhibitors of TDP1 by fragment screening Cancer Research UK2012 - 2015
-
Barts and Brighton ECMC Cancer Research UK2012 - 2017
-
OPPORTUNE - Randomised phase II window study of short-term preoperative treatment with the PI3K inhibitor GDC-0941 plus Anastrozole versus Anastrozole in patients with ER-positive primary breast cancer Genentech2011 - 2015
-
Barts and Brighton Experimental Cancer Medicine Centre Cancer Research UK and NIHR
Publications (77)
- Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer. Save
- Metastatic breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Save
- A Phase 2 study of zelenectide pevedotin, a Bicycle Drug Conjugate, in patients with NECTIN4 amplified advanced breast cancer (Duravelo-3) Save
- A global Phase III, randomized, double-blind trial of BNT327 plus chemotherapy (chemo) vs placebo plus chemo in patients (pts) with previously untreated locally recurrent inoperable or metastatic, PD-L1 negative triple negative breast cancer (TNBC) (ROSE… Save
- ASCENT-04: Analysis of efficacy by biomarker subgroups with sacituzumab govitecan (SG) plus pembrolizumab (pembro) vs chemotherapy (chemo) plus pembro in participants (pts) with previously untreated PD-L1+metastatic triple-negative breast cancer (mTNBC) Save
- ASO Visual Abstract: Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer-Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study Save
- Alpelisib plus fulvestrant for PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer after a CDK4/6 inhibitor (EPIK-B5): Phase III, randomized, double-blind, placebo-controlled, multicenter study Save
- Caught in the Middle: Discrepancies Between Immunohistochemistry and Oncotype DX in Hormone Receptor Assessment Leading to Triple Negative Reclassification-Tumour Heterogeneity or Just Low ER Expression? Save
- Comparative analysis of blood-and tissue-based PIK3CA mutation detection methods in the pivotal Phase 3 INAVO120 trial of palbociclib plus fulvestrant ± inavolisib in hormone receptor-positive, HER2-negative advanced breast cancer Save
- DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer Save
- Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer: results from arms 7 and 8 of the phase Ib/II BEGONIA study Save
- Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial Save
- ELEGANT: Elacestrant (Ela) Versus Standard Endocrine Therapy (ET) in Patients (Pts) With Node-positive, Estrogen Receptor-positive (ER+), HER2-negative (HER2-), Early Breast Cancer (eBC) With High Risk of Recurrence in a Global, Multicenter, Randomized, … Save
- ELEGANT: Elacestrant versus standard endocrine therapy (ET) in women and men with node-positive, estrogen receptor-positive (ER+), HER2-negative (HER2-), early breast cancer (eBC) with high risk of recurrence in a global, multicenter, randomized, open-la… Save
- ELEGANT: Elacestrant versus standard endocrine therapy (ET) in women and men with node-positive, estrogen receptor-positive (ER+), HER2-negative (HER2-), early breast cancer (eBC) with high risk of recurrence in a global, multicenter, randomized, open-la… Save
- Efficacy and safety of giredestrant (GIRE) in patients (pts) with estrogen receptor-positive, HER2-negative early breast cancer (ER+, HER2-eBC) in the phase III lidERA BC clinical trial: Results by menopausal status. Save
- Elegant: elacestrant versus standard endocrine therapy (ET) in women and men with node-positive, estrogen receptor-positive (ER+), HER2-negative (HER2-), early breast cancer (eBC) with high risk of recurrence in a global, multicenter, randomized, open-la… Save
- Evaluating progesterone receptor agonist megestrol plus letrozole for women with early-stage estrogen-receptor-positive breast cancer: the window-of-opportunity, randomized, phase 2b, PIONEER trial Save
- First-line datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) for whom immunotherapy was not an option: Additional efficacy endpoints from the TROPION-Breast0… Save
- First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial Save